TP53 and intrahepatic cholangiocarcinoma: Another clinically relevant difference is the inclusion of a novel entity of MDS/AML in the ICC, but not the WHO-HAEM5, defined by the presence of 10% – 19% blasts in the BM and TP53 mutation or MR abnormality.